|
Nano Approaches to Modulate Host Cell Response for Cancer Therapy
|
5U54CA198999-03
|
$2,636,624
|
$263,662
|
HUANG, LEAF
|
UNIV OF NORTH CAROLINA CHAPEL HILL
|
|
Translational Research in Breast Cancer (SPORE)
|
5P50CA186784-04
|
$2,300,000
|
$138,000
|
OSBORNE, C
|
BAYLOR COLLEGE OF MEDICINE
|
|
DF/HCC Kidney Cancer SPORE
|
5P50CA101942-13
|
$2,300,000
|
$276,000
|
MCDERMOTT, DAVID
|
BETH ISRAEL DEACONESS MEDICAL CENTER
|
|
SPORE in Cervical Cancer
|
5P50CA098252-14
|
$2,300,000
|
$299,000
|
WU, TZYY-CHOOU
|
JOHNS HOPKINS UNIVERSITY
|
|
SPORE: Brain Tumore SPORE Grant
|
5P50CA097257-15
|
$2,300,000
|
$115,000
|
BERGER, MITCHEL
|
UNIVERSITY OF CALIFORNIA, SAN FRANCISCO
|
|
SPORE in Skin Cancer
|
5P50CA174523-04
|
$2,300,000
|
$92,000
|
HERLYN, MEENHARD
|
WISTAR INSTITUTE
|
|
SPORE: Developing New Rationale, Personalized Medicine for Lung Cancer
|
5P50CA070907-19
|
$2,299,998
|
$460,000
|
MINNA, JOHN
|
UT SOUTHWESTERN MEDICAL CENTER
|
|
Duke SPORE in Brain Cancer
|
5P50CA190991-04
|
$2,298,025
|
$91,921
|
SAMPSON, JOHN
|
DUKE UNIVERSITY
|
|
MOTILITY AND INVASION
|
5P01CA100324-15
|
$2,028,990
|
$202,899
|
CONDEELIS, JOHN
|
ALBERT EINSTEIN COLLEGE OF MEDICINE, INC
|
|
Hematopoietic Chimerism after Stem Cell Allografts
|
5P01CA078902-19
|
$2,023,730
|
$951,153
|
STORB, RAINER
|
FRED HUTCHINSON CANCER RESEARCH CENTER
|
|
SPORE in Prostate Cancer
|
5P50CA058236-22
|
$1,993,426
|
$398,685
|
NELSON, WILLIAM
|
JOHNS HOPKINS UNIVERSITY
|
|
ENHANCING T CELL THERAPY OF CANCER
|
5P01CA094237-15
|
$1,932,287
|
$966,144
|
HESLOP, HELEN
|
BAYLOR COLLEGE OF MEDICINE
|
|
Biology and Transplantation of the Hematopoietic Stem Cell
|
5P01CA065493-23
|
$1,914,865
|
$421,270
|
WAGNER, JOHN
|
UNIVERSITY OF MINNESOTA
|
|
Innate Immune Responses and Vaccines Against Tumor-Associated Herpesviruses
|
5P01CA177322-04
|
$1,778,661
|
$142,293
|
SUN, REN
|
UNIVERSITY OF CALIFORNIA LOS ANGELES
|
|
Novel combined immunotherapeutic strategies for glioma: using pet dogs as a large animal spontaneous model
|
1U01CA224160-01
|
$1,632,775
|
$816,388
|
Pluhar, Grace
|
UNIVERSITY OF MINNESOTA
|
|
Adoptive Cell Transfer Immunotherapy of Cancer
|
ZIA BC 010984
|
$1,629,581
|
$651,832
|
Rosenberg, Steven
|
CCR (NCI)
|
|
Gene therapy of cancer
|
ZIA BC 010985
|
$1,629,581
|
$651,832
|
Rosenberg, Steven
|
CCR (NCI)
|
|
Building on the success of the adoptive immunotherapy of cancer
|
ZIA BC 010763
|
$1,562,883
|
$390,721
|
Restifo, Nicholas
|
CCR (NCI)
|
|
Extracellular Vesicles (EVs) and Genes in the Biology and Therapy of Gliomas
|
2P01CA069246-20
|
$1,387,951
|
$610,698
|
BREAKEFIELD, XANDRA
|
MASSACHUSETTS GENERAL HOSPITAL
|
|
Lambda Genetic Networks and Lambda Red-Mediated Recombination
|
ZIA BC 010336
|
$1,316,136
|
$329,034
|
Court, Donald
|
CCR (NCI)
|
|
Telomere Biology
|
ZIA BC 011519
|
$1,268,391
|
$25,368
|
Cooper, Julia
|
CCR (NCI)
|
|
AVGN7, a Novel Gene Therapeutic for Treating Cancer Cachexia
|
1R44CA221539-01
|
$1,206,955
|
$1,206,955
|
RODGERS, BUEL
|
AAVOGEN, INC.
|
|
Optimization of a clinical stage nanoparticle drug delivery platform
|
5R44CA186410-03
|
$998,609
|
$499,305
|
BROWN, BOB
|
DICERNA PHARMACEUTICALS, INC.
|
|
Molecular Basis of Cancer Virus Replication, Transformation, and Innate Defense
|
5P01CA016038-43
|
$980,728
|
$127,495
|
DIMAIO, DANIEL
|
YALE UNIVERSITY
|
|
Initiation of DNA Replication in Mammalian Cells
|
ZIA BC 010411
|
$936,196
|
$140,429
|
Aladjem, Mirit
|
CCR (NCI)
|
|
Cell Production Core Facility
|
ZIC BC 011569
|
$933,290
|
$466,645
|
Somerville, Robert
|
CCR (NCI)
|
|
Surgery Branch Cell Prep Core
|
ZIC BC 010905
|
$933,290
|
$466,645
|
Wunderlich, John
|
CCR (NCI)
|
|
Therapeutic Targeting of Malignant Glioma Stem Cells
|
5R35CA197725-04
|
$916,993
|
$458,497
|
LESNIAK, MACIEJ
|
NORTHWESTERN UNIVERSITY AT CHICAGO
|
|
Identification of non-coding RNAs to therapeutically target undruggable pathways in metastatic lung adenocarcinoma and squamous cell carcinoma
|
5R35CA197452-03
|
$904,402
|
$904,402
|
FLORES, ELSA
|
H. LEE MOFFITT CANCER CTR & RES INST
|
|
Immuno-Targeted Therapy for Melanoma
|
5R35CA197633-03
|
$899,241
|
$269,772
|
RIBAS, ANTONI
|
UNIVERSITY OF CALIFORNIA LOS ANGELES
|
|
Histone Methyltransferases as a Target for Lung Cancer Prevention
|
5R01CA183296-04
|
$778,686
|
$389,343
|
BELINSKY, STEVEN
|
LOVELACE BIOMEDICAL & ENVIRONMENTAL RES
|
|
Adoptive T cell Therapy for Pediatric Leukemia
|
ZIA BC 011565
|
$776,399
|
$232,920
|
Fry, Terry
|
CCR (NCI)
|
|
Harnessing the power of exosomes for non-coding RNA delivery
|
1R35CA209904-01A1
|
$704,789
|
$704,789
|
SOOD, ANIL
|
UNIVERSITY OF TX MD ANDERSON CAN CTR
|
|
Career Development in Pediatric and Medical Oncology
|
5K12CA076930-17
|
$701,719
|
$231,567
|
BERNSTEIN, IRWIN
|
FRED HUTCHINSON CANCER RESEARCH CENTER
|
|
Mechanism, Regulation and Application of miRNA pathway in cancer
|
ZIA BC 011566
|
$686,859
|
$206,058
|
Gu, Shuo
|
CCR (NCI)
|
|
T-cell receptor gene therapy for human papillomavirus-positive cancers
|
ZIA BC 011479
|
$671,060
|
$503,295
|
Hinrichs, Christian
|
CCR (NCI)
|
|
Genetic Analysis of the Multidrug Resistance Phenotype in Tumor Cells
|
ZIA BC 005598
|
$587,732
|
$117,546
|
Gottesman, Michael
|
CCR (NCI)
|
|
Liver Cancer Risk with rAAV Gene Therapy
|
5R01CA190144-03
|
$585,925
|
$585,925
|
GROMPE, MARKUS
|
OREGON HEALTH & SCIENCE UNIVERSITY
|
|
A Phase 1 Study of M032, a Genetically Engineered HSV-1 Expressing IL-12, in Patients with Recurrent/Progressive Glioblastoma Multiforme, Anaplastic Astrocytoma, or Gliosarcoma.
|
1R01CA217179-01
|
$566,814
|
$566,814
|
MARKERT, JAMES
|
UNIVERSITY OF ALABAMA AT BIRMINGHAM
|
|
Targeted therapy of B cell malignances with CAR-T cells of defined composition
|
5R01CA136551-09
|
$560,424
|
$280,212
|
RIDDELL, STANLEY
|
FRED HUTCHINSON CANCER RESEARCH CENTER
|
|
Clinical production of viral vectors for cancer gene therapy
|
ZIC BC 010989
|
$556,461
|
$556,461
|
Feldman, Steven
|
CCR (NCI)
|
|
Leveraging Genetically-Engineered Mice to Optimize Pediatric Glioma Management
|
5R01CA195692-03
|
$551,530
|
$137,883
|
GUTMANN, DAVID
|
WASHINGTON UNIVERSITY
|
|
Mechanisms of resistance to ponatinib therapy in chronic myeloid leukemia
|
5R01CA178397-04
|
$518,975
|
$171,262
|
O'HARE, THOMAS
|
UNIVERSITY OF UTAH
|
|
Mechanisms of Chromosome Maintenance in Bacteria
|
ZIA BC 010277
|
$518,152
|
$51,815
|
Chattoraj, Dhruba
|
CCR (NCI)
|
|
Targeted Delivery of Brain Penetrating DNA Nanoparticles to Brain Tumors
|
5R01CA204968-02
|
$512,053
|
$512,053
|
HANES, JUSTIN
|
JOHNS HOPKINS UNIVERSITY
|
|
Retroviral Replicating Vector-mediated Gene Therapy for Ovarian Cancer
|
1R01CA213119-01A1
|
$504,040
|
$504,040
|
KASAHARA, NORIYUKI
|
UNIVERSITY OF MIAMI SCHOOL OF MEDICINE
|
|
Image-guided radiation-induced permeability (IGRIP) for IGDD
|
5R01CA199663-03
|
$492,442
|
$492,442
|
KRON, STEPHEN
|
UNIVERSITY OF CHICAGO
|
|
Highly Specific and Efficient Vectors for Targeting Pancreatic Cancer
|
5R01CA168712-04
|
$489,556
|
$489,556
|
KELLY, KIMBERLY
|
UNIVERSITY OF VIRGINIA
|
|
IMMUNOBIOLOGY OF NORMAL AND NEOPLASTIC LYMPHOCYTES
|
5T32CA009140-43
|
$480,093
|
$48,009
|
PEAR, WARREN
|
UNIVERSITY OF PENNSYLVANIA
|
|
Tumor Microenvironment in Cancer Progression
|
ZIA BC 011332
|
$474,811
|
$189,924
|
Kaplan, Rosandra
|
CCR (NCI)
|
Total relevant funding to Gene Therapy for this search: $35,689,813
|